Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation
AssigneesThe Board of Trustees of the Leland Stanford Junior University, Trustees of Boston University
InventorsLiang Liang, Michael P. Snyder, Cristina M. Alvira, David N. Cornfield, Lihua Ying, John K. Snyder
Life of this patent
Estimating the term…
Abstract
Methods and formulations of treatment for menstrual complications, gestational complications, and to prolong gestation are described. Treatments include administration of a compound related to regulation of gestational progress or uterine contractions.
Claims88
A method of treating a pregnant individual for recurrent preterm birth, recurrent early term birth, recurrent pregnancy loss, or a short cervix, comprising:
- determining or having determined that a pregnant individual has been diagnosed with recurrent preterm birth, recurrent early term birth, recurrent pregnancy loss, a risk of preterm birth or labor, or a short cervix;
- monitoring the individual during the individual's gestation;
- and
- administering to the individual pregnenolone, a derivative of pregnenolone, a derivative of pregnenolone sulfate, a derivative of 7-methylguanine, or a metabolite within the synthesis pathway thereof to mitigate risks associated with early term birth, preterm birth, preterm labor, pregnancy loss, or a short cervix.
A method of treating a pregnant individual for early term birth, spontaneous preterm birth, preterm labor, or spontaneous abortion, comprising:
- determining or having determined that a pregnant individual is experiencing early term birth, spontaneous preterm birth, preterm labor, or spontaneous abortion;
- and
- administering to the individual at least one tocolytic compound to mitigate uterine contractions, wherein the at least one compound is:
- pregnenolone, a derivative of pregnenolone, a derivative of pregnenolone sulfate, a derivative of 7-methylguanine, or a metabolite within the synthesis pathway thereof.
A method of treating an individual for menorrhagia or dysmenorrhea, comprising:
- determining or having determined that an individual is diagnosed with menorrhagia or dysmenorrhea;
- and
- administering to the individual pregnenolone, a derivative of pregnenolone, a derivative of pregnenolone sulfate, a derivative of 7-methylguanine, or a metabolite within the synthesis pathway thereof to mitigate menorrhagia or dysmenorrhea.
A method of treating a pregnant individual to prolong gestation, comprising:
- determining or having determined that an individual is pregnant;
- and
- prior to the individual having uterine contractions associated with neonatal delivery, administering to the individual pregnenolone, a derivative of pregnenolone, a derivative of pregnenolone sulfate, a derivative of 7-methylguanine, or a metabolite within the synthesis pathway thereof to prolong gestation.
A medicament for use in mitigating uterine contractions in an individual, the medicament comprising:
- pregnenolone, a derivative of pregnenolone, a derivative of pregnenolone sulfate, a derivative of 7-methylguanine, or a metabolite within the synthesis pathway thereof.
A prenatal supplement for use as a prophylaxis during pregnancy, the prenatal supplement comprising:
- estriol-16-glucuronide or an alternative steroidal compound thereof, tetrahydrodeoxycorticosterone (THDOC) or an alternative steroidal compound thereof, androstatne-3,17-diol or an alternative steroidal compound thereof or a derivative thereof or a metabolite within the synthesis pathway thereof, dehydroisoandrosterone sulfate (DHEA-S) or an alternative steroidal compound thereof or a derivative thereof or a metabolite within the synthesis pathway thereof, or pregnenolone or a derivative thereof, pregnenolone sulfate or a derivative thereof, 7-methylguanine or a derivative thereof, or a metabolite within the synthesis pathway thereof.
Dependencies are inferred from the claim text.